Back to top
more

Anavex Life Sciences (AVXL)

(Delayed Data from NSDQ)

$3.87 USD

3.87
702,147

-0.16 (-3.97%)

Updated Jun 7, 2024 04:00 PM ET

After-Market: $3.88 +0.01 (0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for AVXL

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Anavex Life Sciences Corp. [AVXL]

Reports for Purchase

Showing records 81 - 100 ( 156 total )

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 81

04/05/2021

Company Report

Pages: 5

BUY: DSMB - Alzheimer''s Study Should Continue: No Change

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 82

04/01/2021

Company Report

Pages: 5

Alzheimer''s Disease Phase 2/3 Trial Continuation Recommended; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 83

02/19/2021

Company Report

Pages: 9

BUY: We See ANAVEX2-73 as an Undervalued Asset in the CNS Space ? Alzheimer''s, Raising Our Price Target to $19.00 from $16.00

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 84

02/12/2021

Company Report

Pages: 5

F1Q21 Financial Results; Lengthy Cash Runway; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 85

02/08/2021

Company Report

Pages: 5

Recent Stock Appreciation May Portend Further Value Inflection; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 86

12/29/2020

Company Report

Pages: 5

Fiscal 2020 Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 87

12/16/2020

Company Report

Pages: 5

Blarcamesine Positive Phase 2 Rett Syndrome Data; Raising PT to $17

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 88

12/15/2020

Company Report

Pages: 9

BUY: P-Values in N

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 89

11/30/2020

Company Report

Pages: 4

Recent Patent Allowance Could Extend Exclusivity; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 90

11/09/2020

Company Report

Pages: 5

Phase 2 Parkinson''s Disease Data Indicates Path Forward; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 91

11/06/2020

Company Report

Pages: 10

BUY: Anavex2-73 Phase 2 Data at CTAD

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 92

10/21/2020

Company Report

Pages: 5

Positive Phase 2 Parkinson''s Disease Data; Raising PT to $14

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 93

10/15/2020

Company Report

Pages: 8

BUY: Anavex2-73 Phase 2 Trial Demonstrates Proof of Concept

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 94

08/11/2020

Company Report

Pages: 5

Parkinson''s Dementia Data Imminent; F3Q20 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 95

07/07/2020

Company Report

Pages: 4

Second Pipeline Candidate Enters Clinical Development; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 96

07/01/2020

Company Report

Pages: 8

Excellent. Anavex2-73 Enrolls First Phase 2/3 Patient in Rett Syndrome (EXCELLENCE) Trial

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 97

06/16/2020

Company Report

Pages: 8

BUY: Anavex2-73 Exceeds Enrollment Target in Rett Syndrome Trial

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 98

06/16/2020

Company Report

Pages: 4

Enrollment Target Substantially Exceeded in Rett Syndrome Phase 2 Trial; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 99

06/05/2020

Company Report

Pages: 4

Alzheimer''s Disease Trial Geographic Expansion; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Anavex Life Sciences Corp.

Industry: Medical - Biomedical and Genetics

Record: 100

05/22/2020

Company Report

Pages: 4

ANAVEX?3-71 Enters First-in-Human Phase 1 Trial; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party